Aurobindo Pharma Limited

NSE: AUROPHARMA · Healthcare · Lot size: 550

OverviewOption ChainOI AnalysisFII / DIIMax Pain

Aurobindo Pharma Limited Share Price & Analysis

₹1,458Updated 5 Jun 2026, 03:30 pm IST
LTP
₹1,458
—
Open
₹1,483.9
High
₹1,496.5
Low
₹1,456
Close
₹1,463.6
52W High
₹1,550
52W Low
₹1,016
Volume
1282K
Lot Size
550
Sector
Healthcare
Market Cap
₹83K Cr
Face Value
₹1
Large CapNIFTY 200NIFTY 500MIDCAP 100

Price Chart

Fundamentals

P/E
23.4
Sector P/E
48.9
P/B
2.24
EPS
₹60.04
ROE
10.1%
ROCE
12.8%
D/E Ratio
0.21
Div Yield
0.28%
Book Value
₹652
+

Strengths

  • ✓Attractively valued vs sector (P/E 23.4x vs industry 48.9x)
  • ✓Low debt relative to equity (D/E 0.2x)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
₹1,783
₹4.3L Cr34.45.121620.50.07
DIVISLAB
Divi's Laboratories Limited
₹6,616
₹1.7L Cr66.110.4816.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
₹4,416
₹1.5L Cr66.417.8127.615.40.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
₹8,315
₹1.2L Cr59.512.6222.117.90.88
CIPLA
Cipla Limited
₹1,402
₹1.1L Cr27.33.2912.416.60.01
ZYDUSLIFE
Zydus Lifesciences Limited
₹1,091
₹1.1L Cr204.0521.221.20.38
DRREDDY
Dr. Reddy's Laboratories Limited
₹1,283
₹1.1L Cr25.42.8311.813.60.16

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

AUROPHARMA · as of Mar 2026

Promoters51.82%
FII15.33%▼0.96
DII26.23%▲1.02
Public6.61%▼0.06
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters51.84%51.84%51.80%51.82%51.82%51.82%
FII20.72%18.01%16.73%16.59%16.29%15.33%
DII20.60%23.28%24.77%25.14%25.21%26.23%
Public6.85%6.87%6.69%6.45%6.67%6.61%

Corporate Events

To consider and approve the financial results for the period ended March 31, 2026

Results20 May 2026

Buy Back

Buy Back16 Apr 2026

Interim Dividend - Rs 4 Per Share

Dividend7 Aug 2025

Annual General Meeting

AGM25 Aug 2024

Buy Back

Buy Back29 Jul 2024

Interim Dividend - Rs 1.50 Per Share

Dividend19 Feb 2024

Interim Dividend - Rs 3 Per Share

Dividend19 Nov 2023

Annual General Meeting

AGM21 Aug 2023

Latest News

All news →

Aurobindo gets USFDA nod for Tofacitinib tablets

*Aurobindo gets USFDA nod for Tofacitinib tablets* — Aurobindo Pharma has received final approval from the USFDA for its generic Tofacitinib tablets, used to treat rheumatoid arthritis. The approval allows the company to launch the product immediately, expanding its footprint in the US market. This positions Aurobindo to capture a share of the **$1.2 billion** annual market. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Indian Pharma Post2d ago
Medium Impact

Aurobindo Pharma gets USFDA nod for Tofacitinib tablets

*Aurobindo Pharma gets USFDA nod for Tofacitinib tablets* — Shares rise on approval of generic drug for rheumatoid arthritis. The greenlight allows Aurobindo to market **Tofacitinib** in **60 mg strength**, boosting its US portfolio. This expands its presence in the **$XX million** chronic inflammation market. Approval may contribute to future revenue growth. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Moneycontrol.com2d ago
Medium Impact

Aurobindo Pharma gets USFDA nod for Tofacitinib tablets

*Aurobindo Pharma gets USFDA nod for Tofacitinib tablets* — Aurobindo Pharma has received USFDA approval for Tofacitinib tablets, a generic version of Xeljanz. The drug is used to treat rheumatoid arthritis and other inflammatory conditions. This approval expands Aurobindo’s presence in the US generics market. Launch timing and market share impact remain to be seen. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Business Standard2d ago
Medium Impact

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹8.6K Cr
▲4.3%
₹8.3K Cr
▲5.3%
₹7.9K Cr
▼6.1%
₹8.4K Cr
▲5.1%
₹8.0K Cr
▲2.3%
₹7.8K Cr
▲3.0%
₹7.6K Cr
▼0.2%
₹7.6K Cr
Op. Profit
₹1.8K Cr
▲5.7%
₹1.7K Cr
▲4.7%
₹1.6K Cr
▼8.9%
₹1.8K Cr
▲11.5%
₹1.6K Cr
▲0.8%
₹1.6K Cr
▼3.2%
₹1.6K Cr
▼2.5%
₹1.7K Cr
OPM
21.0%
▲5.0%
20.0%
▲0.0%
20.0%
▼4.8%
21.0%
▲5.0%
20.0%
▲0.0%
20.0%
▼4.8%
21.0%
▼4.5%
22.0%
Net Profit
₹910 Cr
▲7.3%
₹848 Cr
▲2.9%
₹824 Cr
▼8.7%
₹903 Cr
▲6.7%
₹846 Cr
▲3.5%
₹817 Cr
▼11.0%
₹918 Cr
▲1.2%
₹907 Cr
EPS (₹)
15.67
▲7.3%
14.61
▲2.9%
14.2
▼8.7%
15.56
▲6.9%
14.56
▲3.5%
14.07
▼10.3%
15.69
▲1.2%
15.51

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Revenue
₹33.7K Cr
▲6.1%
₹31.7K Cr
▲9.4%
₹29.0K Cr
▲16.7%
₹24.9K Cr
▲6.0%
₹23.5K Cr
▼5.3%
₹24.8K Cr
▲7.3%
₹23.1K Cr
▲18.1%
₹19.6K Cr
▲18.8%
₹16.5K Cr
▲10.4%
₹14.9K Cr
Expenses
₹26.8K Cr
▲6.5%
₹25.2K Cr
▲8.6%
₹23.2K Cr
▲9.6%
₹21.1K Cr
▲11.0%
₹19.1K Cr
▼2.2%
₹19.5K Cr
▲6.8%
₹18.2K Cr
▲16.9%
₹15.6K Cr
▲23.0%
₹12.7K Cr
▲10.7%
₹11.5K Cr
Op. Profit
₹6.8K Cr
▲4.5%
₹6.6K Cr
▲12.4%
₹5.8K Cr
▲57.2%
₹3.7K Cr
▼15.7%
₹4.4K Cr
▼16.7%
₹5.3K Cr
▲8.8%
₹4.8K Cr
▲22.7%
₹4.0K Cr
▲4.8%
₹3.8K Cr
▲9.6%
₹3.4K Cr
OPM
20.0%
▼4.8%
21.0%
▲5.0%
20.0%
▲33.3%
15.0%
▼21.1%
19.0%
▼9.5%
21.0%
▲0.0%
21.0%
▲5.0%
20.0%
▼13.0%
23.0%
▲0.0%
23.0%
Other Income
₹428 Cr
▼31.2%
₹622 Cr
▲69.9%
₹366 Cr
▲25.8%
₹291 Cr
▲91.4%
₹152 Cr
▼95.2%
₹3.2K Cr
▲1824.7%
₹166 Cr
▲137.1%
₹70 Cr
▼33.3%
₹105 Cr
▼8.7%
₹115 Cr
Interest
₹384 Cr
▼16.0%
₹457 Cr
▲57.6%
₹290 Cr
▲107.1%
₹140 Cr
▲185.7%
₹49 Cr
▼33.8%
₹74 Cr
▼75.7%
₹305 Cr
▲16.0%
₹263 Cr
▲237.2%
₹78 Cr
▲16.4%
₹67 Cr
Depreciation
₹1.8K Cr
▲7.8%
₹1.6K Cr
▲8.3%
₹1.5K Cr
▲22.2%
₹1.2K Cr
▲10.5%
₹1.1K Cr
▲6.8%
₹1.1K Cr
▲9.1%
₹967 Cr
▲44.8%
₹668 Cr
▲19.7%
₹558 Cr
▲30.4%
₹428 Cr
PBT
₹5.1K Cr
▲0.9%
₹5.1K Cr
▲15.7%
₹4.4K Cr
▲67.7%
₹2.6K Cr
▼22.6%
₹3.4K Cr
▼54.1%
₹7.3K Cr
▲96.2%
₹3.7K Cr
▲21.1%
₹3.1K Cr
▼4.6%
₹3.2K Cr
▲5.9%
₹3.1K Cr
Tax %
31.0%
▲0.0%
31.0%
▲10.7%
28.0%
▲7.7%
26.0%
▲18.2%
22.0%
▼18.5%
27.0%
▲12.5%
24.0%
▲0.0%
24.0%
▼4.0%
25.0%
▲0.0%
25.0%
Net Profit
₹3.5K Cr
▲0.5%
₹3.5K Cr
▲9.9%
₹3.2K Cr
▲64.4%
₹1.9K Cr
▼27.2%
₹2.6K Cr
▼50.4%
₹5.3K Cr
▲87.6%
₹2.8K Cr
▲20.3%
₹2.4K Cr
▼2.4%
₹2.4K Cr
▲5.3%
₹2.3K Cr
EPS (₹)
60.34
▲0.5%
60.02
▲10.8%
54.15
▲64.6%
32.9
▼27.2%
45.2
▼50.4%
91.05
▲87.5%
48.56
▲20.3%
40.36
▼2.4%
41.36
▲5.3%
39.29
Div Payout
0.0%
0.0%
▼100.0%
8.0%
▼65.2%
23.0%
▲15.0%
20.0%
▲400.0%
4.0%
▼33.3%
6.0%
▲0.0%
6.0%
▲0.0%
6.0%
▲0.0%
6.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemSep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Liabilities
Equity Capital
₹58 Cr
▲0.0%
₹58 Cr
▼1.7%
₹59 Cr
▲0.0%
₹59 Cr
▲0.0%
₹59 Cr
▲0.0%
₹59 Cr
▲0.0%
₹59 Cr
▲0.0%
₹59 Cr
▲0.0%
₹59 Cr
▲0.0%
₹59 Cr
Reserves
₹35.0K Cr
▲7.3%
₹32.6K Cr
▲9.4%
₹29.8K Cr
▲11.2%
₹26.8K Cr
▲9.2%
₹24.5K Cr
▲12.1%
₹21.9K Cr
▲30.4%
₹16.8K Cr
▲21.2%
₹13.8K Cr
▲19.0%
₹11.6K Cr
▲24.8%
₹9.3K Cr
Borrowings
₹7.8K Cr
▼5.7%
₹8.3K Cr
▲24.3%
₹6.6K Cr
▲25.8%
₹5.3K Cr
▲85.4%
₹2.9K Cr
▼46.6%
₹5.3K Cr
▼8.4%
₹5.8K Cr
▼16.4%
₹7.0K Cr
▲46.1%
₹4.8K Cr
▲41.8%
₹3.4K Cr
Other Liabilities
₹9.7K Cr
▲13.4%
₹8.6K Cr
▲4.1%
₹8.2K Cr
▲11.5%
₹7.4K Cr
▲18.8%
₹6.2K Cr
▲1.0%
₹6.1K Cr
▲0.6%
₹6.1K Cr
▲12.9%
₹5.4K Cr
▲20.5%
₹4.5K Cr
▲29.7%
₹3.5K Cr
Total Liabilities
₹52.5K Cr
▲6.2%
₹49.5K Cr
▲10.7%
₹44.7K Cr
▲13.2%
₹39.5K Cr
▲17.4%
₹33.6K Cr
▲0.7%
₹33.4K Cr
▲16.2%
₹28.8K Cr
▲9.5%
₹26.3K Cr
▲25.4%
₹20.9K Cr
▲29.3%
₹16.2K Cr
Assets
Fixed Assets
₹17.7K Cr
▲19.9%
₹14.8K Cr
▲2.1%
₹14.5K Cr
▲31.5%
₹11.0K Cr
▲4.7%
₹10.5K Cr
▲12.4%
₹9.4K Cr
▼0.2%
₹9.4K Cr
▲10.9%
₹8.5K Cr
▲30.0%
₹6.5K Cr
▲34.9%
₹4.8K Cr
CWIP
₹3.0K Cr
▼38.0%
₹4.9K Cr
▲26.6%
₹3.9K Cr
▼28.2%
₹5.4K Cr
▲43.8%
₹3.7K Cr
▲22.4%
₹3.1K Cr
▲54.2%
₹2.0K Cr
▲19.1%
₹1.7K Cr
▲5.4%
₹1.6K Cr
▲8.6%
₹1.5K Cr
Investments
₹268 Cr
▲6.3%
₹252 Cr
▼32.3%
₹372 Cr
▼31.5%
₹543 Cr
▼45.5%
₹997 Cr
▲68.7%
₹591 Cr
▲6.5%
₹555 Cr
▲54.2%
₹360 Cr
▲15.4%
₹312 Cr
▲26.8%
₹246 Cr
Other Assets
₹31.5K Cr
▲6.6%
₹29.5K Cr
▲13.7%
₹26.0K Cr
▲15.2%
₹22.5K Cr
▲22.8%
₹18.4K Cr
▼9.9%
₹20.4K Cr
▲21.2%
₹16.8K Cr
▲6.7%
₹15.8K Cr
▲25.9%
₹12.5K Cr
▲29.7%
₹9.7K Cr
Total Assets
₹52.5K Cr
▲6.2%
₹49.5K Cr
▲10.7%
₹44.7K Cr
▲13.2%
₹39.5K Cr
▲17.4%
₹33.6K Cr
▲0.7%
₹33.4K Cr
▲16.2%
₹28.8K Cr
▲9.5%
₹26.3K Cr
▲25.4%
₹20.9K Cr
▲29.3%
₹16.2K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Operating CF
₹3.9K Cr
▲61.2%
₹2.4K Cr
▲2.0%
₹2.4K Cr
▼52.4%
₹5.0K Cr
▲50.7%
₹3.3K Cr
▼24.0%
₹4.4K Cr
▲165.4%
₹1.7K Cr
▼15.5%
₹2.0K Cr
▼40.4%
₹3.3K Cr
▲130.9%
₹1.4K Cr
Investing CF
₹-1.9K Cr
▲56.0%
₹-4.2K Cr
▼6.8%
₹-4.0K Cr
▼23.7%
₹-3.2K Cr
▼637.9%
₹597 Cr
▲138.2%
₹-1.6K Cr
▲46.2%
₹-2.9K Cr
▼50.7%
₹-1.9K Cr
▼7.8%
₹-1.8K Cr
▼23.6%
₹-1.4K Cr
Financing CF
₹120 Cr
▼85.0%
₹800 Cr
▼55.9%
₹1.8K Cr
▲161.1%
₹-3.0K Cr
▼117.5%
₹-1.4K Cr
▲29.9%
₹-1.9K Cr
▼201.5%
₹1.9K Cr
▲122.1%
₹864 Cr
▲145.1%
₹-1.9K Cr
▼624.7%
₹365 Cr
Net Cash Flow
₹2.2K Cr
▲316.3%
₹-1.0K Cr
▼537.8%
₹230 Cr
▲119.8%
₹-1.2K Cr
▼145.5%
₹2.6K Cr
▲194.0%
₹871 Cr
▲30.8%
₹666 Cr
▼25.3%
₹892 Cr
▲310.4%
₹-424 Cr
▼224.7%
₹340 Cr
Free Cash Flow
₹1.4K Cr
▲232.0%
₹-1.1K Cr
▼230.3%
₹-323 Cr
▼112.0%
₹2.7K Cr
▲79.2%
₹1.5K Cr
▼49.4%
₹3.0K Cr
▲2504.4%
₹114 Cr
▼84.0%
₹714 Cr
▼55.2%
₹1.6K Cr
▲1191.8%
₹-146 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Debtor Days
66d
▲8.2%
61d
▼7.6%
66d
▲6.5%
62d
▲19.2%
52d
▼23.5%
68d
▲6.3%
64d
▼5.9%
68d
▲0.0%
68d
▼44.3%
122d
Inventory Days
295d
▲3.9%
284d
▲3.3%
275d
▲1.1%
272d
▼18.3%
333d
▲15.2%
289d
▼4.9%
304d
▼4.1%
317d
▲28.9%
246d
▲2.5%
240d
Days Payable
117d
▼9.3%
129d
▲3.2%
125d
▲28.9%
97d
▼5.8%
103d
▲6.2%
97d
▼9.3%
107d
▼16.4%
128d
▲4.9%
122d
▼16.4%
146d
Cash Conv. Cycle
244d
▲13.0%
216d
▲0.0%
216d
▼8.9%
237d
▼16.0%
282d
▲8.5%
260d
▲0.0%
260d
▲1.2%
257d
▲34.6%
191d
▼12.0%
217d
Working Capital Days
49d
▼25.8%
66d
▲20.0%
55d
▼34.5%
84d
▲61.5%
52d
▲48.6%
35d
▲40.0%
25d
▼50.0%
50d
▼2.0%
51d
▲15.9%
44d
ROCE
14.0%
▲0.0%
14.0%
▲55.6%
9.0%
▼30.8%
13.0%
▼27.8%
18.0%
▼5.3%
19.0%
▲5.6%
18.0%
▼21.7%
23.0%
▼8.0%
25.0%
▼7.4%
27.0%

Source: Screener.in · Lower days = better efficiency

Deep Dive Analysis

Option Chain
Strike-wise OI & IV
OI Analysis
PCR, buildup type
FII / DII
Institutional flows
Max Pain
Writer pain levels

About Aurobindo Pharma Limited

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Healthcare · Pharmaceuticals & Biotechnology

Related Analysis

Same Sector

ALKEM
Alkem Laboratories Limited
Neutral
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Neutral
BIOCON
Biocon Limited
Neutral
CIPLA
Cipla Limited
Neutral
DIVISLAB
Divi's Laboratories Limited
Neutral

Frequently Asked Questions

What is Aurobindo Pharma Limited share price today?▾
Aurobindo Pharma Limited (AUROPHARMA) is currently trading at ₹1,458 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Aurobindo Pharma Limited available in F&O (Futures & Options)?▾
Yes, Aurobindo Pharma Limited (AUROPHARMA) is part of the NSE F&O segment with a lot size of 550 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Aurobindo Pharma Limited 52-week high and low?▾
Aurobindo Pharma Limited's 52-week high is ₹1,550 and the 52-week low is ₹1,016. The current price of ₹1,458 is 5.9% below the 52W high.
What is Aurobindo Pharma Limited P/E ratio?▾
Aurobindo Pharma Limited's current P/E ratio is 23.4. This indicates the market is paying ₹23.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Aurobindo Pharma Limited options?▾
Aurobindo Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 550 shares). To trade AUROPHARMA options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.